Home » Stocks » FMTX

Forma Therapeutics Holdings, Inc. (FMTX)

Stock Price: $24.97 USD -0.69 (-2.67%)
Updated Apr 19, 2021 2:36 PM EDT - Market open
Market Cap 1.28B
Revenue (ttm) 7.44M
Net Income (ttm) -74.15M
Shares Out 47.37M
EPS (ttm) -3.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $24.97
Previous Close $25.65
Change ($) -0.69
Change (%) -2.67%
Day's Open 25.50
Day's Range 24.59 - 26.13
Day's Volume 126,260
52-Week Range 22.51 - 56.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featu...

2 weeks ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results from Q4 and full year 2020, as well as business updates.

2 weeks ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive data from the 600 mg cohort in the Phase 1 trial of FT-4202 in sickle cell patients.

2 weeks ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that the company will release fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021.

3 weeks ago - Business Wire

Forma Therapeutics (FMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces participation in three upcoming investor conferences.

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that renowned doctor Selwyn M. Vickers, M.D., has been elected to the company's board of directors.

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

4 months ago - Business Wire

WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics launches a proposed public offering of 4,600,000 shares of its common stock.

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics presents clinical proof-of-concept data on FT-4202 in sickle cell disease at the 62nd ASH annual meeting.

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces financial results for the third quarter ended September 30, 2020.

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces EU Orphan Drug designation for FT-4202 for the treatment of sickle cell disease.

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma announced that four abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma today announced that company management will participate in three upcoming investor conferences.

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive top-line data from planned interim analysis of Phase 2 trial evaluating olutasidenib in acute myeloid leukemia.

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointments of two new vice presidents

7 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointment of Thomas G.

7 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that Wayne A.I.

8 months ago - Business Wire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, IMRA, KROS, PCVX, RNA, RPTX, XBI ...
9 months ago - CNN Business

Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.

Other stocks mentioned: RPTX
9 months ago - GuruFocus

About FMTX

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2020
Stock Exchange
NASDAQ
Ticker Symbol
FMTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for FMTX stock is "Strong Buy." The 12-month stock price forecast is 60.67, which is an increase of 143.02% from the latest price.

Price Target
$60.67
(143.02% upside)
Analyst Consensus: Strong Buy